www.g4media.ro/medicamentele-pentru-slabit-pot-duc

The FDA has mandated that successful weight loss drugs like Ozempic and Zepbound include warnings about a rare eye condition that can lead to permanent vision loss. This condition, known as non-arteritic anterior ischemic optic neuropathy (NAION), has been linked to GLP-1 medications. The FDA's decision follows a comprehensive analysis revealing a potential increased risk of NAION among patients using these drugs. Reports indicate that approximately 28 million Americans are on GLP-1 medications, with many discontinuing use due to gastrointestinal side effects. Patients are advised to be aware of NAION symptoms, such as blurred vision and color distortion.